会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • METHOD OF ALLEVIATING NEUROPATHIC PAIN
    • 治疗神经痛疼痛的方法
    • WO1998039357A1
    • 1998-09-11
    • PCT/US1997016062
    • 1997-09-11
    • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    • THE REGENTS OF THE UNIVERSITY OF CALIFORNIAO'BRIEN, John, S.
    • C07K04/00
    • C07K14/475A61K38/00
    • The invention provides a method of alleviating neuropathic pain in a subject by administering a neuropathic pain alleviating amount of prosaposin receptor agonist to the subject. The invention also provides a method of inhibiting the onset of neuropathic pain in a subject by administering neuropathic pain alleviating amount of prosaposin receptor agonist to the subject. The present invention also provides prosaposin receptor agonists and the use of these agonists for stimulating neurite outgrowth, inhibiting neural cell death, promoting myelination and inhibiting neural demyelination. In addition, there is provided a method of inhibiting sensory or motor neuropathy by contacting neuronal cells with a composition comprising an effective inhibiting amount of prosaposin receptor agonist.
    • 本发明提供了一种减轻受试者神经性疼痛的方法,该方法是通过对受试者施用神经性疼痛缓解量的prosaposin受体激动剂。 本发明还提供一种抑制受试者神经性疼痛发作的方法,该方法是向受试者施用神经性疼痛缓解量的prosaposin受体激动剂。 本发明还提供了prosaposin受体激动剂和这些激动剂用于刺激神经突生长,抑制神经细胞死亡,促进髓鞘形成和抑制神经脱髓鞘的用途。 此外,提供了通过使神经元细胞与包含有效抑制量的前列腺素受体激动剂的组合物接触来抑制感觉或运动神经病的方法。
    • 5. 发明申请
    • T CELL ANTIGEN RECEPTOR PEPTIDES
    • T细胞抗原受体肽
    • WO1997047644A1
    • 1997-12-18
    • PCT/AU1997000367
    • 1997-06-11
    • NORTHERN SYDNEY AREA HEALTH SERVICESMANOLIOS, Nicholas
    • NORTHERN SYDNEY AREA HEALTH SERVICES
    • C07K04/00
    • C07K14/7051A61K38/00
    • The present invention provides peptides which affect T-cells, presumably by action on the T-cell antigen receptor. The present invention further relates to the therapy of various inflammatory and autoimmune disease states involving the use of these peptides. Specifically, the peptides are useful in the treatment of disorders where T-cells are involved or recruited. In one aspect the peptides have the formula: R1-A-B-A-R2 in which A is a hydrophobic amino acid or a hydrophobic peptide sequence comprising between 2 and 10 amino acids; B is a charged amino acid; R1 is NH2 and R2 is COOH. In another aspect the peptides have the formula: R1-A-B-C-R2 in which A is a peptide sequence of between 0 and 5 amino acids; B is cysteine; C is a peptide sequence of between 2 to 10 amino acids; R1 is NH2; and R2 is COOH.
    • 本发明提供了可能通过对T细胞抗原受体的作用影响T细胞的肽。 本发明还涉及涉及使用这些肽的各种炎性和自身免疫性疾病的治疗。 具体地,这些肽可用于治疗涉及或招募T细胞的疾病。 一方面,肽具有下式:R1-A-B-A-R2,其中A是疏水性氨基酸或包含2至10个氨基酸的疏水性肽序列; B是带电荷的氨基酸; R1是NH2,R2是COOH。 另一方面,所述肽具有下式:R1-A-B-C-R2,其中A是0至5个氨基酸的肽序列; B是半胱氨酸; C是2至10个氨基酸的肽序列; R1是NH2; R2为COOH。
    • 7. 发明申请
    • COMPOUNDS FOR REVERSING DRUG RESISTANCE
    • 化学药物抵抗耐药性
    • WO1995031474A1
    • 1995-11-23
    • PCT/IB1994000144
    • 1994-05-12
    • SARKADI, BalazsSOPRODI, JanosCSUKA, OrsolyaMAGOCSI, MariaMEZO, ImrePALYI, IstvanTEPLAN, IstvanVADASZ, ZsoltVINCZE, Borbala
    • C07K04/00
    • C07K5/06113A61K38/00C07K5/0215C07K5/0606C07K5/06078C07K5/06086C07K5/06104
    • The invention features novel peptide derivatives called Reversins, and provides for their use in a method of reducing the activity of the multi-drug transporter protein MDR1 in order to overcome multidrug resistance in a mammal. The peptide derivatives are of the formula (I) X n-X -X (X )n-X , wherein n is 0 or 1, and each n is the same or different; X is BOC, BOC-Asu, Z-Asu, benzyloxycarbonyl, Glu(OBzl)-OBzl, Trp-OMe, Trp-Phe-OMe, Phe-Trp-OMe, Phe-Phe-OtBu, Trp-Trp-OtBu, indoloacetyl, benzoyl, an alkylamine of 1-4 carbons, dibenzylamide, tryptamide, 1-amino-adamantine, aminomethylcyclohexane, indoline, phenylethylamide or dicyclohexylamide; X is Glu(OBzl), Asp(OBzl), succinyl, O,O-dibenzoyltartaroyl, diphenoyl, muconyl, Thx, Cpa, Asu, Nal, Pen, Phg, Dbt, Lys(BOC), Lys(Z), Cys(Bzl), Thr(Bzl), Glu(OtBu), tert.-Leu, Leu, Nle, Pro, Phe, Tyr(Bzl), or Ser(Bal); X is Asp, Asu, Lys, Glu, Trp, Thx, Cpa, Nal, Pen, Phg, Dbt, Glu(OtBu), tert.-Leu, Leu, Nle, Pro, Tyr, Phe, or Tyr(Bzl); X is BOC-Glu(OBzl), Glu(OBzl), Asu, OBzl, Bzl, BOC, BOC-Lys(BOC), Z-Glu(OtBu), Asp(OBzl), Asp(OBz)-OBzl, benzyloxycarbonyl, O-(cyclo-hexyl), fluorenylmethyl ester, Glu(OtBu), Glu(OtBu)-OBzl, 1-amino-adamantine, aminomethylcyclohexane, indoline, phenylethylamide, or dicyclohexylamide; and X is OMe, OBzl, OtBu, Phe-OMe, -O-(cyclohexyl), Trp-OMe, (chlorophenyl)-isobutylamide, fluorenylmethyl ester, ONp, 1-aminoadamantane, aminomethylcyclohexane, indoline, phenylethylamide, or dicyclohexylamide.
    • 本发明的特征在于新颖的肽衍生物,称为Reversins,并且它们用于降低多药物转运蛋白MDR1活性的方法,以克服哺乳动物的多药耐药性。 肽衍生物具有式(I)X 1 -X-X 2 -X 3(X 4)n -X 5,其中n为0或1,并且各n相同或不同; X 1是BOC,BOC-Asu,Z-Asu,苄氧基羰基,Glu(OBzl)-OBz1,Trp-OMe,Trp-Phe-OMe,Phe-Trp-OMe,Phe-Phe-OtBu,Trp-Trp- OtBu,吲哚乙酰基,苯甲酰基,1-4个碳的烷基胺,二苄酰胺,胰蛋白酶,1-氨基 - 金刚烷,氨基甲基环己烷,二氢吲哚,苯乙酰胺或二环己基酰胺; X 2是Glu(OBzl),Asp(OBzl),琥珀酰基,O,O-二苯甲酰基联苯酰基,二苯甲酰基,粘蛋白,Thx,Cpa,Asu,Nal,Pen,Phg,Dbt,Lys(BOC),Lys(Z) ,Cys(Bzl),Thr(Bzl),Glu(OtBu),叔-Leu,Leu,Nle,Pro,Phe,Tyr(Bzl)或Ser(Bal) X 3是Asp,Asu,Lys,Glu,Trp,Thx,Cpa,Nal,Pen,Phg,Dbt,Glu(OtBu),叔Leu,Leu,Nle,Pro,Tyr,Phe或Tyr BZL); X 4是BOC-Glu(OBzl),Glu(OBzl),Asu,OBz1,Bzl,BOC,BOC-Lys(BOC),Z-Glu(OtBu),Asp(OBzl),Asp(OBz) ,苄氧基羰基,O-(环己基),芴基甲基酯,Glu(OtBu),Glu(OtBu)-OBzl,1-氨基 - 金刚烷,氨基甲基环己烷,二氢吲哚,苯乙酰胺或二环己基酰胺; 并且X 5是OMe,OBzl,OtBu,Phe-OMe,-O-(环己基),Trp-OMe,(氯苯基) - 异丁基酰胺,芴甲基酯,ONp,1-氨基甲烷基环戊烷,氨基甲基环己烷,二氢吲哚,苯乙基酰胺或二环己基酰胺 。